Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
furosemide + salbutamol
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
A combination therapy consisting of nebulized furosemide and salbutamol (albuterol). Furosemide, traditionally known as a loop diuretic, demonstrates bronchodilator and anti-inflammatory effects when nebulized. Salbutamol is a short-acting, selective beta-2 adrenergic receptor agonist. When combined, these medications show enhanced efficacy in improving respiratory parameters in patients with COPD and reactive airway disease. The combination therapy has been shown to significantly improve spirometry indices including FEV1, FVC, and FEV1/FVC ratios, as well as reduce dyspnea scores compared to either agent alone.
- Other names
- furosemide + albuterol
02
Targets
CA (Carbonic anhydrase)GPR35 (G-protein Coupled Receptor 35)ADRB2 (β2)NKCC (Sodium-potassium-chloride cotransporter)
Beyond the preview
Go deeper on furosemide + salbutamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on furosemide + salbutamol.